Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are drugs containing the active ingredient ferric carboxymaltose in a parenteral dosage form. The subject of the agreement are drugs containing the active ingredient rivaroxaban in a divided oral dosage form. The contract covers medicinal products containing the active ingredient rotigotine.

Opportunity closing date

01 October 2025

Value of contract

£0-100k